Close Menu

NEW YORK – Bayer and Canadian diagnostics firm LifeLabs said on Wednesday that they have launched a program to offer free genetic testing to identify rare NTRK gene fusions in cancer patients in Canada who may be eligible for targeted treatment.

NTRK fusions occur in less than 1 percent of solid tumors. In 2019, Health Canada approved larotrectinib (Bayer's Vitrakvi) for adults and pediatric patients with refractory solid tumors who have NTRK fusions and are out of treatment options. This was the first time regulators in Canada approved a tissue-agnostic indication for a drug.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.